{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:44:00Z","timestamp":1788536640430,"version":"build-2803163510"},"reference-count":61,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,3,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>For many years there has been considerable disassociation between the understood biology of chronic lymphocytic leukemia (CLL) and the therapeutics used to treat this disease. With the introduction of the first targeted CD20 antibody rituximab and its addition to chemotherapy came the first observation that minimal residual disease\u2013negative (MRD-negative) complete responses (CRs) could be obtained with dramatically improved progression-free survival and overall survival. This advance was soon to be surpassed by the introduction of therapeutics that target B-cell receptor (BCR) signaling. New data show that BCR-inhibiting agents are very active for the treatment of relapsed CLL, despite the lack of MRD-negative CR, with durability of response being considerably more impressive than previously observed with other agents not producing MRD-negative CRs. This perspective provides a view of where these agents may take us in the future as CLL therapy evolves with this exciting new class of drugs.<\/jats:p>","DOI":"10.1182\/blood-2013-09-453092","type":"journal-article","created":{"date-parts":[[2014,1,7]],"date-time":"2014-01-07T04:29:37Z","timestamp":1389068977000},"page":"1455-1460","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":52,"title":["How will B-cell-receptor\u2013targeted therapies change future CLL therapy?"],"prefix":"10.1182","volume":"123","author":[{"given":"Jeffrey A.","family":"Jones","sequence":"first","affiliation":[{"name":"Division of Medicinal Chemistry, College of Pharmacy, and"},{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"16","key":"2019111818422408100_B1","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1182\/blood-2011-06-338855","article-title":"B-cell receptor signaling in chronic lymphocytic leukemia.","volume":"118","author":"Stevenson","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2019111818422408100_B2","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2012-02-362624","article-title":"The B-cell receptor signaling pathway as a therapeutic target in CLL.","volume":"120","author":"Woyach","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2019111818422408100_B3","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1084\/jem.194.11.1639","article-title":"Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.","volume":"194","author":"Rosenwald","year":"2001","journal-title":"J Exp Med"},{"issue":"12","key":"2019111818422408100_B4","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2002-10-3306","article-title":"ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.","volume":"101","author":"Wiestner","year":"2003","journal-title":"Blood"},{"issue":"5","key":"2019111818422408100_B5","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1182\/blood-2006-12-062265","article-title":"ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia.","volume":"111","author":"Chen","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2019111818422408100_B6","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.","volume":"117","author":"Herishanu","year":"2011","journal-title":"Blood"},{"issue":"13","key":"2019111818422408100_B7","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1158\/0008-5472.CAN-08-4252","article-title":"Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.","volume":"69","author":"Buchner","year":"2009","journal-title":"Cancer Res"},{"issue":"37","key":"2019111818422408100_B8","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1038\/onc.2009.179","article-title":"The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.","volume":"28","author":"Baudot","year":"2009","journal-title":"Oncogene"},{"issue":"12","key":"2019111818422408100_B9","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-\u03b4 inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.","volume":"116","author":"Herman","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2019111818422408100_B10","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1182\/blood-2012-09-457119","article-title":"Targeting the LYN\/HS1 signaling axis in chronic lymphocytic leukemia.","volume":"121","author":"ten Hacken","year":"2013","journal-title":"Blood"},{"issue":"23","key":"2019111818422408100_B11","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"key":"2019111818422408100_B12","author":"Milara"},{"issue":"13","key":"2019111818422408100_B13","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"issue":"23","key":"2019111818422408100_B14","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1200\/JCO.2012.43.3748","article-title":"Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia.","volume":"30","author":"Cheson","year":"2012","journal-title":"J Clin Oncol"},{"key":"2019111818422408100_B15","article-title":"Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies.","author":"Hallek","journal-title":"Blood"},{"issue":"13","key":"2019111818422408100_B16","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019111818422408100_B17","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"issue":"5583","key":"2019111818422408100_B18","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.1073560","article-title":"Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice.","volume":"297","author":"Okkenhaug","year":"2002","journal-title":"Science"},{"key":"2019111818422408100_B19","author":"Brown"},{"key":"2019111818422408100_B20","author":"Uno"},{"issue":"10","key":"2019111818422408100_B21","doi-asserted-by":"crossref","first-page":"6598","DOI":"10.4049\/jimmunol.177.10.6598","article-title":"Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells.","volume":"177","author":"Patton","year":"2006","journal-title":"J Immunol"},{"issue":"8","key":"2019111818422408100_B22","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.4049\/jimmunol.177.8.5122","article-title":"The p110delta isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells.","volume":"177","author":"Okkenhaug","year":"2006","journal-title":"J Immunol"},{"issue":"29","key":"2019111818422408100_B23","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2019111818422408100_B24","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2019111818422408100_B25","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","article-title":"The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.","volume":"119","author":"de Rooij","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111818422408100_B26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies.","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111818422408100_B27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111818422408100_B28","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1182\/blood-2006-01-011817","article-title":"Bruton tyrosine kinase is essential for botrocetin\/VWF-induced signaling and GPIb-dependent thrombus formation in vivo.","volume":"108","author":"Liu","year":"2006","journal-title":"Blood"},{"issue":"20","key":"2019111818422408100_B29","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0960-9822(98)70471-3","article-title":"A role for Bruton\u2019s tyrosine kinase (Btk) in platelet activation by collagen.","volume":"8","author":"Quek","year":"1998","journal-title":"Curr Biol"},{"issue":"1","key":"2019111818422408100_B30","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1046\/j.1365-2141.2001.02905.x","article-title":"Bruton\u2019s tyrosine kinase is present in normal platelets and its absence identifies patients with X-linked agammaglobulinaemia and carrier females.","volume":"114","author":"Futatani","year":"2001","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111818422408100_B31","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"9","key":"2019111818422408100_B32","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.","volume":"30","author":"B\u00f6ttcher","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111818422408100_B33","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"2019111818422408100_B34","author":"Marin"},{"key":"2019111818422408100_B35","author":"Efficace"},{"key":"2019111818422408100_B36","author":"Kelley"},{"key":"2019111818422408100_B37","author":"Wu"},{"issue":"6","key":"2019111818422408100_B38","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","article-title":"Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.","volume":"25","author":"Darkow","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"2019111818422408100_B39","author":"Zhang"},{"issue":"3","key":"2019111818422408100_B40","doi-asserted-by":"crossref","first-page":"257","DOI":"10.6004\/jnccn.2013.0037","article-title":"Non-Hodgkin\u2019s lymphomas, version 1.2013.","volume":"11","author":"Zelenetz","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"2019111818422408100_B41","article-title":"ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia.","author":"Pospisilova","journal-title":"Leukemia"},{"key":"2019111818422408100_B42","author":"Chang"},{"key":"2019111818422408100_B43","author":"Jaglowski"},{"key":"2019111818422408100_B44","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.187.187","article-title":"The Btk inhibitor ibrutinib (PCI-32765) in combination with rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia (CLL) patients [abstract].","volume":"120","author":"Burger","year":"2012","journal-title":"Blood"},{"key":"2019111818422408100_B45","author":"O\u2019Brien"},{"key":"2019111818422408100_B46","author":"Barrientos"},{"issue":"9747","key":"2019111818422408100_B47","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"15","key":"2019111818422408100_B48","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2019111818422408100_B49","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.4049\/jimmunol.178.6.3575","article-title":"Differential regulation of human NK cell-mediated cytotoxicity by the tyrosine kinase Itk.","volume":"178","author":"Khurana","year":"2007","journal-title":"J Immunol"},{"issue":"6","key":"2019111818422408100_B50","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.4049\/jimmunol.156.6.2143","article-title":"Regulation of B cell survival in xid mice by the proto-oncogene bcl-2.","volume":"156","author":"Woodland","year":"1996","journal-title":"J Immunol"},{"issue":"9","key":"2019111818422408100_B51","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1182\/blood.V91.9.3379","article-title":"Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses.","volume":"91","author":"Kitada","year":"1998","journal-title":"Blood"},{"key":"2019111818422408100_B52","author":"Seymour"},{"key":"2019111818422408100_B53","author":"Wobus"},{"issue":"3","key":"2019111818422408100_B54","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.clim.2008.04.009","article-title":"CC-4047 promotes Th1 cell differentiation and reprograms polarized human Th2 cells by enhancing transcription factor T-bet.","volume":"128","author":"Xu","year":"2008","journal-title":"Clin Immunol"},{"issue":"14","key":"2019111818422408100_B55","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2019111818422408100_B56","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"issue":"20","key":"2019111818422408100_B57","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1182\/blood-2012-12-470005","article-title":"Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).","volume":"121","author":"Shanafelt","year":"2013","journal-title":"Blood"},{"key":"2019111818422408100_B58","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial.","author":"O\u2019Brien","year":"2014","journal-title":"Lancet Oncol"},{"key":"2019111818422408100_B59","author":"Wiestner"},{"key":"2019111818422408100_B60","author":"O\u2019Brien"},{"issue":"21","key":"2019111818422408100_B61","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199805213382104","article-title":"Chlorambucil in indolent chronic lymphocytic leukemia.","volume":"338","author":"Dighiero","year":"1998","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/123\/10\/1455\/1374473\/1455.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/123\/10\/1455\/1374473\/1455.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T13:42:43Z","timestamp":1688910163000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/123\/10\/1455\/32369\/How-will-Bcellreceptortargeted-therapies-change"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,6]]},"references-count":61,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,3,6]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2013-09-453092","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,6]]}}}